Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Review Special Issue Series: Recent Advances in Cardiovascular Medicine, 2nd...
share announcement

Review Special Issue Series: Recent Advances in Cardiovascular Medicine, 2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: 20 February 2025 | Viewed by 7927

Special Issue Editor

Prof. Dr. Nandu Goswami

E-Mail Website
Guest Editor
1. Division of Physiology, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Auenbruggerpl. 2, 8036 Graz, Austria
2. Center for Spaceflight and Aviation Health, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates
Interests: cardiovascular system; heart rate variability; gravitational adaptation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is my pleasure to invite you to contribute to the Special Issue entitled “Review Special Issue Series: Recent Advances in Cardiovascular Medicine, 2nd Edition”. In our previous Special Issue entitled “Review Special Issue Series: Recent Advances in Cardiovascular Medicine”, we collected high-standard review papers covering a wide range of topics. This is a continuation of the previous series.

This Special Issue series, entitled “Recent Advances in Cardiovascular Medicine”, is a compilation of review articles that highlight the latest research findings and advancements in the field of cardiovascular medicine. This series focuses on providing a comprehensive overview of various topics, including diagnostic techniques, therapeutic interventions, and emerging trends in cardiovascular health. By featuring expert reviews, this Special Issue offers valuable insights and critical analyses of the current state of research in cardiovascular medicine.

Prof. Dr. Nandu Goswami
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular medicine
  • recent advances
  • review articles
  • diagnostic techniques
  • therapeutic interventions
  • emerging trends
  • cardiovascular health
  • expert analysis
  • research

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

12 pages, 890 KiB  
Review
Exercise in Postural Orthostatic Tachycardia Syndrome: Focus on Individualized Exercise Approach
by Kristine Zeznick Trimble, Jennifer N. Switzer and Svetlana Blitshteyn
J. Clin. Med. 2024, 13(22), 6747; https://doi.org/10.3390/jcm13226747 - 9 Nov 2024
Cited by 1 | Viewed by 4390
Abstract
Exercise is a vital component of health and is commonly utilized as a non-pharmacologic therapy for many disorders, including postural orthostatic tachycardia syndrome (POTS). However, exercise intolerance is a key feature of POTS and other autonomic disorders and, therefore, presents a major barrier [...] Read more.
Exercise is a vital component of health and is commonly utilized as a non-pharmacologic therapy for many disorders, including postural orthostatic tachycardia syndrome (POTS). However, exercise intolerance is a key feature of POTS and other autonomic disorders and, therefore, presents a major barrier for many patients. Despite exercise being uniformly recommended as a therapeutic intervention, a majority of patients with POTS, especially those with severe orthostatic intolerance and fatigue, are unable to complete or sustain rigorous exercise programs or successfully integrate them into their daily routine. In this narrative review, we discuss the current literature on exercise and POTS and our clinical experience with a home-based exercise approach developed at the Dysautonomia Clinic. We conclude that individualized exercise programs that are delivered remotely by a certified physical therapist may be convenient, easily accessible, and safe for patients with POTS, especially those with severe symptoms who may be home- or bedbound. Future randomized controlled studies are needed to quantify and characterize the benefits of home-based exercise programs delivered remotely compared to standard therapy. Full article
(This article belongs to the Special Issue Review Special Issue Series: Recent Advances in Cardiovascular Medicine, 2nd Edition)
►▼ Show Figures

Figure 1

14 pages, 1214 KiB  
Review
Finerenone: A Third-Generation MRA and Its Impact on Cardiovascular Health—Insights from Randomized Controlled Trials
by Michael Sabina, Jennifer Trube, Shrinand Shah, Andrew Lurie, Mason Grimm and Anas Bizanti
J. Clin. Med. 2024, 13(21), 6398; https://doi.org/10.3390/jcm13216398 - 25 Oct 2024
Viewed by 3159
Abstract
Introduction: Finerenone, a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), offers a targeted approach to managing cardiovascular outcomes, particularly in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Unlike traditional MRAs such as spironolactone and eplerenone, which can cause off-target hormonal [...] Read more.
Introduction: Finerenone, a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), offers a targeted approach to managing cardiovascular outcomes, particularly in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Unlike traditional MRAs such as spironolactone and eplerenone, which can cause off-target hormonal side effects and hyperkalemia, Finerenone selectively binds to mineralocorticoid receptors, reducing these risks. Recent randomized controlled trials have demonstrated Finerenone’s potential to improve cardiovascular outcomes, making it a promising alternative in the management of heart failure and other cardiovascular conditions associated with CKD and T2D. Methods: We conducted a scoping review using PRISMA guidelines. A search for “Finerenone” in the PubMed, Embase, and Cochrane Library databases included randomized controlled trials (RCTs), post hoc analyses, and relevant meta-analyses on cardiovascular outcomes. Data were synthesized narratively, assessing study quality through strengths and limitations. Discussion: Finerenone has shown significant benefits and a superior safety profile compared with traditional MRAs like spironolactone and eplerenone in managing CKD, T2D, and heart failure. It effectively reduces cardiovascular and renal events while minimizing risks such as hyperkalemia and hormonal side effects associated with steroidal MRAs. Future studies, including the REDEFINE-HF, FINALITY-HF, and CONFIRMATION-HF trials, will further explore Finerenone’s potential across diverse heart failure phenotypes, including its role in heart failure with mildly reduced and preserved ejection fractions, potentially establishing it as a cornerstone therapy in heart failure management. Conclusions: Finerenone represents a significant advancement in MRA therapy, offering enhanced safety and efficacy in managing cardiovascular outcomes in CKD and T2D patients. The current evidence supports its use as a promising alternative to traditional MRAs, particularly in patients intolerant to steroidal MRAs. Further trials are needed to fully establish its potential across diverse patient populations, including those with varying heart failure phenotypes. Full article
(This article belongs to the Special Issue Review Special Issue Series: Recent Advances in Cardiovascular Medicine, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop